An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma

[1]  Athena W Wong,et al.  An anti-apoptotic HEK293 cell line provides a robust and high titer platform for transient protein expression in bioreactors , 2019, mAbs.

[2]  K. Rabe,et al.  Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma , 2018, The New England journal of medicine.

[3]  W. Forrest,et al.  Dual functionality of β-tryptase protomers as both proteases and cofactors in the active tetramer , 2018, The Journal of Biological Chemistry.

[4]  B. Hargadon,et al.  Airway pathological heterogeneity in asthma: Visualization of disease microclusters using topological data analysis , 2018, The Journal of allergy and clinical immunology.

[5]  P. Berger,et al.  Lung function parameters in omalizumab responder patients: An interesting tool? , 2017, Allergy.

[6]  L. Biesecker,et al.  A common haplotype containing functional CACNA1H variants is frequently coinherited with increased TPSAB1 copy number , 2017, Genetics in Medicine.

[7]  Andrew J. Oler,et al.  Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number , 2016, Nature Genetics.

[8]  Xinzhong Dong,et al.  Different activation signals induce distinct mast cell degranulation strategies. , 2016, The Journal of clinical investigation.

[9]  Christopher E Brightling,et al.  Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. , 2016, The Lancet. Respiratory medicine.

[10]  S. Wenzel,et al.  Current concepts of severe asthma. , 2016, The Journal of clinical investigation.

[11]  T. Zuberbier,et al.  Phenotypic variability in human skin mast cells , 2016, Experimental dermatology.

[12]  J. Arron,et al.  Biomarkers in the clinical development of asthma therapies. , 2016, Biomarkers in medicine.

[13]  D. Greiner,et al.  Humanized mouse model of mast cell-mediated passive cutaneous anaphylaxis and passive systemic anaphylaxis. , 2015, The Journal of allergy and clinical immunology.

[14]  J. Fahy.  Type 2 inflammation in asthma — present in most, absent in many , 2014, Nature Reviews Immunology.

[15]  Joakim S. Dahlin,et al.  Mouse Mast Cell Protease-6 and MHC Are Involved in the Development of Experimental Asthma , 2014, The Journal of Immunology.

[16]  K. Ansel,et al.  A miRNA upregulated in asthma airway T cells promotes TH2 cytokine production , 2014, Nature Immunology.

[17]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[18]  Tobin R Sosnick,et al.  Folding of a large protein at high structural resolution , 2013, Proceedings of the National Academy of Sciences.

[19]  S Walter Englander,et al.  Protein hydrogen exchange at residue resolution by proteolytic fragmentation mass spectrometry analysis , 2013, Proceedings of the National Academy of Sciences.

[20]  Athena W Wong,et al.  Use of an anti‐apoptotic CHO cell line for transient gene expression , 2013, Biotechnology progress.

[21]  W. Busse,et al.  Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. , 2013, American journal of respiratory and critical care medicine.

[22]  L. Mayne,et al.  Minimizing Back Exchange in the Hydrogen Exchange-Mass Spectrometry Experiment , 2012, Journal of The American Society for Mass Spectrometry.

[23]  M. Tsai,et al.  IgE and mast cells in allergic disease , 2012, Nature Medicine.

[24]  I. Morize,et al.  Structure-based library design and the discovery of a potent and selective mast cell β-tryptase inhibitor as an oral therapeutic agent. , 2012, Bioorganic & medicinal chemistry letters.

[25]  E. Di Cera,et al.  Allostery in trypsin-like proteases suggests new therapeutic strategies. , 2011, Trends in biotechnology.

[26]  Nicola A Hanania,et al.  Lebrikizumab treatment in adults with asthma. , 2011, The New England journal of medicine.

[27]  Leland Mayne,et al.  Many Overlapping Peptides for Protein Hydrogen Exchange Experiments by the Fragment Separation-Mass Spectrometry Method , 2011, Journal of the American Society for Mass Spectrometry.

[28]  S. Mosesova,et al.  Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. , 2011, The Journal of allergy and clinical immunology.

[29]  W. Busse,et al.  Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy , 2011, Annals of Internal Medicine.

[30]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[31]  C. Brightling,et al.  Mast Cell Fibroblastoid Differentiation Mediated by Airway Smooth Muscle in Asthma , 2010, The Journal of Immunology.

[32]  M. Solon,et al.  Accumulation of intraepithelial mast cells with a unique protease phenotype in T(H)2-high asthma. , 2010, The Journal of allergy and clinical immunology.

[33]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[34]  N. Trivedi,et al.  Mast cell peptidases: chameleons of innate immunity and host defense. , 2010, American journal of respiratory cell and molecular biology.

[35]  P. Kwok,et al.  Human subjects are protected from mast cell tryptase deficiency despite frequent inheritance of loss-of-function mutations. , 2009, The Journal of allergy and clinical immunology.

[36]  Barmak Modrek,et al.  T-helper type 2-driven inflammation defines major subphenotypes of asthma. , 2009, American journal of respiratory and critical care medicine.

[37]  C. Brightling,et al.  Mast Cells Promote Airway Smooth Muscle Cell Differentiation via Autocrine Up-Regulation of TGF-β11 , 2008, The Journal of Immunology.

[38]  H. Kido,et al.  Mast cell tryptase and photoaging: possible involvement in the degradation of extra cellular matrix and basement membrane proteins , 2008, Archives of Dermatological Research.

[39]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[40]  I. Pavord,et al.  Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma , 2007, Thorax.

[41]  M. Bogyo,et al.  Development of activity-based probes for trypsin-family serine proteases. , 2006, Bioorganic & medicinal chemistry letters.

[42]  G. Pejler,et al.  Biology of mast cell tryptase , 2006 .

[43]  C. Brightling,et al.  Mast cell migration to Th2 stimulated airway smooth muscle from asthmatics , 2006, Thorax.

[44]  L. Schwartz,et al.  The B12 Anti-Tryptase Monoclonal Antibody Disrupts the Tetrameric Structure of Heparin-Stabilized β-Tryptase to Form Monomers That Are Inactive at Neutral pH and Active at Acidic pH1 , 2006, The Journal of Immunology.

[45]  J. Vernejoux,et al.  Fraktalkine Produced by Airway Smooth Muscle Cells Contributes to Mast Cell Recruitment in Asthma1 , 2006, The Journal of Immunology.

[46]  M. Hollenberg,et al.  Inhibitors of Tryptase as Mast Cell-Stabilizing Agents in the Human Airways: Effects of Tryptase and Other Agonists of Proteinase-Activated Receptor 2 on Histamine Release , 2004, Journal of Pharmacology and Experimental Therapeutics.

[47]  Lauren Cohn,et al.  Asthma: mechanisms of disease persistence and progression. , 2004, Annual review of immunology.

[48]  G. Bisacchi,et al.  Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors. , 2002, Bioorganic & medicinal chemistry letters.

[49]  I. Pavord,et al.  Mast-cell infiltration of airway smooth muscle in asthma. , 2002, The New England journal of medicine.

[50]  A. Ammit,et al.  Human mast cell and airway smooth muscle cell interactions: implications for asthma. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[51]  R. Marthan,et al.  Tryptase and agonists of PAR-2 induce the proliferation of human airway smooth muscle cells. , 2001, Journal of applied physiology.

[52]  K. Alving,et al.  Heparin antagonists are potent inhibitors of mast cell tryptase. , 2001, Biochemistry.

[53]  R. Djukanović,et al.  Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. , 2001, The Journal of allergy and clinical immunology.

[54]  D. Dripps,et al.  Inhibition of allergen-induced pulmonary responses by the selective tryptase inhibitor 1,5-bis-[4-[(3-carbamimidoyl-benzenesulfonylamino)-methyl]-phenoxy]-pen tane (AMG-126737). , 1999, Biochemical pharmacology.

[55]  W. Bode,et al.  The structure of the human betaII-tryptase tetramer: fo(u)r better or worse. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[56]  C. Huang,et al.  Human Tryptases α and β/II Are Functionally Distinct Due, in Part, to a Single Amino Acid Difference in One of the Surface Loops That Forms the Substrate-binding Cleft* , 1999, The Journal of Biological Chemistry.

[57]  M. Pallaoro,et al.  Characterization of Genes Encoding Known and Novel Human Mast Cell Tryptases on Chromosome 16p13.3* , 1999, The Journal of Biological Chemistry.

[58]  R. Huber,et al.  Human β-tryptase is a ring-like tetramer with active sites facing a central pore , 1998, Nature.

[59]  S. Suh,et al.  Kunitz-type soybean trypsin inhibitor revisited: refined structure of its complex with porcine trypsin reveals an insight into the interaction between a homologous inhibitor from Erythrina caffra and tissue-type plasminogen activator. , 1998, Journal of molecular biology.

[60]  C. Baumgarten,et al.  Human tryptase fibrinogenolysis is optimal at acidic pH and generates anticoagulant fragments in the presence of the anti-tryptase monoclonal antibody B12. , 1997, Journal of immunology.

[61]  A. Walls,et al.  Human mast cell tryptase: a stimulus of microvascular leakage and mast cell activation. , 1997, European journal of pharmacology.

[62]  R. Tanaka,et al.  Lactoferrin, a potent tryptase inhibitor, abolishes late-phase airway responses in allergic sheep. , 1997, American journal of respiratory and critical care medicine.

[63]  J. Cairns,et al.  Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. , 1997, The Journal of clinical investigation.

[64]  H. Wolfson,et al.  Shape complementarity at protein–protein interfaces , 1994, Biopolymers.

[65]  L. Presta,et al.  X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. , 1993, Journal of molecular biology.

[66]  E. Tam,et al.  Degradation of airway neuropeptides by human lung tryptase. , 1990, American journal of respiratory cell and molecular biology.

[67]  L. Schwartz,et al.  Immunologic and physicochemical evidence for conformational changes occurring on conversion of human mast cell tryptase from active tetramer to inactive monomer. Production of monoclonal antibodies recognizing active tryptase. , 1990, Journal of immunology.

[68]  J. Nadel,et al.  Mast cell tryptase and chymase reverse airway smooth muscle relaxation induced by vasoactive intestinal peptide in the ferret. , 1989, The Journal of pharmacology and experimental therapeutics.

[69]  D. Metcalfe,et al.  Regulation of human mast cell tryptase. Effects of enzyme concentration, ionic strength and the structure and negative charge density of polysaccharides. , 1987, The Biochemical journal.

[70]  L. Schwartz,et al.  Regulation of tryptase from human lung mast cells by heparin. Stabilization of the active tetramer. , 1986, The Journal of biological chemistry.

[71]  L. Schwartz,et al.  The fibrinogenolytic activity of purified tryptase from human lung mast cells. , 1985, Journal of immunology.

[72]  K.,et al.  Tryptase from human pulmonary mast cells. Purification and characterization. , 1981, The Journal of biological chemistry.

[73]  R. Huber,et al.  Structural basis of the activation and action of trypsin , 1978 .

[74]  S. Willsie.  Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma , 2010 .

[75]  T. Kuwabara,et al.  Shortening of the induction period of allergic asthma in cynomolgus monkeys by Ascaris suum and house dust mite. , 2008, Journal of pharmacological sciences.

[76]  G. Pejler,et al.  Biology of mast cell tryptase. An inflammatory mediator. , 2006, The FEBS journal.

[77]  G. Pejler,et al.  Structural requirements and mechanism for heparin-dependent activation and tetramerization of human betaI- and betaII-tryptase. , 2005, Journal of molecular biology.

[78]  Ram Seshadri.  Crystal structures , 2004 .

[79]  L. Schwartz,et al.  Expression of alpha-tryptase and beta-tryptase by human basophils. , 2004, The Journal of allergy and clinical immunology.

[80]  P. Afonine,et al.  research papers Acta Crystallographica Section D Biological , 2003 .

[81]  K. McDowell,et al.  Pathophysiology of asthma. , 2000, Respiratory care clinics of North America.

[82]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[83]  Z. Cohen,et al.  Ultrastructural evidence for piecemeal and anaphylactic degranulation of human gut mucosal mast cells in vivo. , 1992, International archives of allergy and immunology.

[84]  L. Schwartz,et al.  Interactions of human mast cell tryptase with biological protease inhibitors. , 1990, Archives of biochemistry and biophysics.

[85]  J. Nadel,et al.  Mast cell tryptase causes airway smooth muscle hyperresponsiveness in dogs. , 1989, The Journal of clinical investigation.